- Ana Sayfa
- Ücretsiz Uygulama Analitiği
- PneumoRecs VaxAdvisor
- PneumoRecs VaxAdvisor Vs. ASCVD Risk Estimator Plus
PneumoRecs VaxAdvisor vs ASCVD Risk Estimator Plus Kullanım & İstatistikleri
This is the PneumoRecs VaxAdvisor App created by the Centers for Disease Control and Prevention (CDC) in collaboration with the Georgia Tech Research Institute. PneumoRecs VaxAdvisor provides patient-specific pneumococcal vaccination guidance consistent with the pneumococcal vaccination recommendations of the Advisory Committee on Immunization Practices. Vaccination providers enter a patient’s age and respond to prompts about the patient’s pneumococcal vaccination history and underlying medical conditions. The app then displays patient-specific pneumococcal vaccination recommendations consistent with the recommended U.S. immunization schedule.
- Apple App Store
- BOŞTA
- Medikal
Mağaza Sıralaması
- -
The updated ASCVD Risk Estimator Plus uses up to date science and user feedback to help a clinician and patient build a customized risk lowering plan by estimating and monitoring change in 10-year ASCVD risk.
Use the app to:
• Estimate a patient’s initial 10-year ASCVD risk using the pooled cohort equation
• Receive an individualized, risk-based, intervention approach
• Project the impact of specific interventions on a patient’s risk
• Guide clinician-patient discussion around customizing an intervention plan
• Update risk at follow-up based on a patient’s response to therapy using the Million Hearts Longitudinal model
Advice from the app is derived from the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, the 2018 ACC/AHA et.al Guideline on the Management of Blood Cholesterol, the 2017 ACC/AHA et.al Guideline on High Blood Pressure in Adults, the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk, and the 2016 Million Hearts Longitudinal ASCVD Risk Assessment Tool user guide. The information and recommendations in this app are meant to support clinical decision making. They are not meant to represent the only or best course of care, or replace clinical judgment. Therapeutic options should be determined after discussion between the patient and their care provider.
- Apple App Store
- BOŞTA
- Medikal
Mağaza Sıralaması
- -
PneumoRecs VaxAdvisor ile ASCVD Risk Estimator Plus için sıralama karşılaştırması
Son 28 gündeki PneumoRecs VaxAdvisor sıralama trendini ASCVD Risk Estimator Plusile karşılaştırın
Rank
Mevcut veri yok
PneumoRecs VaxAdvisor vs. ASCVD Risk Estimator Plus ülke karşılaştırmasına göre sıralama
Son 28 gündeki PneumoRecs VaxAdvisor sıralama trendini ASCVD Risk Estimator Plusile karşılaştırın
Tüm kategoriler
Mevcut veri yok
Medikal
Ücretsiz deneme sürümümüzü kullanarak istediğiniz siteyle karşılaştırın
PneumoRecs VaxAdvisor VS.
ASCVD Risk Estimator Plus
Ocak 17, 2025